Aim. The protein AIMP1/p43, which is a component of the high molecular weight complex of aminoacyl-tRNA synthetases in higher eukaryotes, and its C-terminal domain is the cytokine EMAP II (endothelial and monocyte-activating polypeptide II) are known for their ability to inhibit neoangiogenesis and induce apoptosis of cancer cells. A significant role of AIMP1/p43 and EMAP II in pro-inflammatory processes has been identified, which have become a prerequisite for their use as immunomodulatory and anticancer drugs for targeted therapy. The development of pharmaceutical dosage forms involves the use of additional chemical components and excipients, such as 2-hydroxypropyl-β-cyclodextrin (HP-β-CD). Conclusions. To sum up, the nanocomposite complexes with biomedical ligands stabilize the molecules of AIMP1/p43 and EMAP II proteins. The created nanocomposite complexes are promising therapeutic agents, which requires further research on the possibility of their implementation in clinical practice for the treatment of cancer.